June 2, 2022 — Today, GE Healthcare issued a statement that it expects production capacity from its Shanghai facility to be close to 100% starting Monday, June 6, following the easing of local COVID-19 restrictions. The statement noted that this will enable GE to restabilize our global supply of iodinated contrast media. GE stated that it will continue to work with impacted customers to help them plan several weeks ahead as supply progressively recovers.
In an April 19 letter to consumers, GE Healthcare announced it would be limiting orders of iohexol. The facility has since reopened with production output currently at 50% and expected to increase. GE Healthcare has also expanded production capacity at its manufacturing site in Cork, Ireland. You can read the full report here.
Related Content of MRI Gadolinium Concerns
AJR Publishes Best Practices for Iodinated Contrast Media Shortage
Voluntary Dismissal of Chuck Norris Gadolinium Case Involving Bracco
VIDEO: How Serious is MRI Gadolinium Retention in the Brain and Body? An interview with Max Wintermark, M.D.
VIDEO “Big Concerns Remain for MRI Gadolinium Contrast Safety at RSNA 2017,” An interview with Emanuel Kanal, M.D.
Radiology Has Failed to Properly Assess or Track MRI Gadolinium Contrast Safety
Recent Developments in Contrast Media
FDA Committee Votes to Expand Warning Labels on Gadolinium-Based Contrast Agents
European Medicines Agency Issues Update on Gadolinium Contrast Agents
July 25, 2024 
